Website
N/ATelephone
61.8.6478.7816
Address
1257 Hay Street West Perth, Western Australia (WA) 6005
Description
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). It uses artificial intelligence (AI) to improve the detection and management of coronary artery disease. The company was founded by John Windsor Barrington and John Konstantopoulos on January 24, 2018 and is headquartered in West Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.17 - 0.57
Trade Value (12mth)
AU$3,657.00
1 week
0%
1 month
5.26%
YTD
-55.06%
1 year
-54.55%
All time high
1.75
EPS 3 yr Growth
721.400%
EBITDA Margin
N/A
Operating Cashflow
-$11m
Free Cash Flow Return
-29.30%
ROIC
-30.40%
Interest Coverage
-204.70
Quick Ratio
14.90
Shares on Issue (Fully Dilluted)
78m
HALO Sector
Technology
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 March 23 |
Change of Director's Interest Notice - B Ridgeway
×
Change of Director's Interest Notice - B Ridgeway |
31 March 22 |
Notification regarding unquoted securities - AYA
×
Notification regarding unquoted securities - AYA |
31 January 22 |
Quarterly Activity Report and Appendix 4C for Q2 FY22
×
Quarterly Activity Report and Appendix 4C for Q2 FY22 |
31 August 23 |
Appendix 4E and Annual Financial Report - 30 June 2023
×
Appendix 4E and Annual Financial Report - 30 June 2023 |
31 August 22 |
Appendix 4E and Annual Financial Report 30 June 2022
×
Appendix 4E and Annual Financial Report 30 June 2022 |
31 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 November 23 |
Chair and CEO Annual General Meeting Address
×
Chair and CEO Annual General Meeting Address |
30 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 June 22 |
Change of Director's Interest Notice - John Barrington
×
Change of Director's Interest Notice - John Barrington |
29 November 23 |
Annual General Meeting - Link
×
Annual General Meeting - Link |
29 March 22 |
Artrya Opens US Operations in Los Angeles
×
Artrya Opens US Operations in Los Angeles |
29 March 22 |
Change of Director's Interest Notice - Bernie Ridgeway
×
Change of Director's Interest Notice - Bernie Ridgeway |
28 November 22 |
Change in Substantial Holding - Artrya
×
Change in Substantial Holding - Artrya |
28 March 23 |
Notification regarding unquoted securities - AYA
×
Notification regarding unquoted securities - AYA |
27 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
27 October 23 |
2023 Annual Report
×
2023 Annual Report |
27 October 23 |
2023 Corporate Governance Statement and Appendix 4G
×
2023 Corporate Governance Statement and Appendix 4G |
27 October 22 |
Artrya Successful in Gaining European Regulatory Approval
×
Artrya Successful in Gaining European Regulatory Approval |
27 November 23 |
Ceasing to be a Substantial Holder - Artrya Limited
×
Ceasing to be a Substantial Holder - Artrya Limited |
27 November 23 |
Application for quotation of securities - AYA
×
Application for quotation of securities - AYA |
27 March 23 |
Board and Management Changes
×
Board and Management Changes |
27 March 23 |
Proposed issue of securities - AYA
×
Proposed issue of securities - AYA |
27 March 23 |
Final Director's Interest Notice - J Barrington
×
Final Director's Interest Notice - J Barrington |
27 July 22 |
Updated Appendix 4C for Q4 FY22
×
Updated Appendix 4C for Q4 FY22 |
27 April 23 |
Becoming a substantial holder
×
Becoming a substantial holder |
26 July 22 |
Quarterly Activity Report and Appendix 4C for Q4 FY22
×
Quarterly Activity Report and Appendix 4C for Q4 FY22 |
26 April 22 |
Application for quotation of securities - AYA
×
Application for quotation of securities - AYA |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.